BCAX
NASDAQBicara Therapeutics Inc.
News25/Ratings12
News · 26 weeks74-44%
2025-10-262026-04-19
Mix4990d
- Insider21(43%)
- Other10(20%)
- SEC Filings10(20%)
- Offering4(8%)
- Analyst2(4%)
- Earnings2(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Hyep Ivan4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 4 filed by Mazumdar Claire4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECSEC Form 144 filed by Bicara Therapeutics Inc.144 - Bicara Therapeutics Inc. (0002023658) (Subject)
- INSIDERSEC Form 4 filed by Cohlhepp Ryan4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)
- PRBicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on April 1, 2026 to one new employee under Bicara's 2026 Inducement Plan as a material inducement to employment. The employee received a non-qualified stock option to purchase 44,175 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $20.50 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on April 1, 2026. One-fourth of the shares vest on the first anniversa
- SECSEC Form 10-K filed by Bicara Therapeutics Inc.10-K - Bicara Therapeutics Inc. (0002023658) (Filer)
- SECBicara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
- PRBicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateSelected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading and every-three-week maintenance dose of ficerafusp alfa Corporate call to discuss financial results and business updates on Monday, March 30, 2026 at 8:30 a.m. ET BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided a business update. "Bicara enters the year with exceptional momentum across our clinical, regulatory, and corporate priorities," said Cla
- INSIDERSEC Form 4 filed by Raben David4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- ANALYSTBofA Securities initiated coverage on Bicara Therapeutics with a new price targetBofA Securities initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $35.00
- INSIDERSEC Form 4 filed by Hyep Ivan4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- PRBicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ETBOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To acces
- INSIDERSEC Form 4 filed by Mazumdar Claire4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECSEC Form 144 filed by Bicara Therapeutics Inc.144 - Bicara Therapeutics Inc. (0002023658) (Subject)
- INSIDERPresident and COO Cohlhepp Ryan sold $245,714 worth of shares (12,500 units at $19.66) and exercised 8,000 shares at a strike of $3.79, decreasing direct ownership by 2% to 200,641 units (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 4 filed by Bicara Therapeutics Inc.4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERChief Executive Officer Mazumdar Claire exercised 8,234 shares at a strike of $3.79 and sold $154,325 worth of shares (8,234 units at $18.74) (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERPresident and COO Cohlhepp Ryan exercised 12,892 shares at a strike of $3.79 and sold $315,893 worth of shares (17,392 units at $18.16), decreasing direct ownership by 2% to 205,141 units (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERChief Financial Officer Hyep Ivan exercised 16,518 shares at a strike of $3.79 and sold $300,971 worth of shares (16,518 units at $18.22) (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERChief Medical Officer Raben David exercised 16,500 shares at a strike of $3.79 and sold $305,610 worth of shares (16,500 units at $18.52) (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECSEC Form 144 filed by Bicara Therapeutics Inc.144 - Bicara Therapeutics Inc. (0002023658) (Subject)
- PRBicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on March 2, 2026 to one new employee under Bicara's 2026 Inducement Plan as a material inducement to employment. The employee received a non-qualified stock option to purchase 115,000 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $17.59 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on March 2, 2026. One-fourth of the shares vest on the first annivers
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Bicara Therapeutics Inc.SCHEDULE 13D/A - Bicara Therapeutics Inc. (0002023658) (Subject)
- INSIDERDirector Ra Capital Management, L.P. bought $4,800,000 worth of shares (300,000 units at $16.00) (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)